Semple P F
University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
J Hypertens Suppl. 1995 Sep;13(3):S17-21. doi: 10.1097/00004872-199509003-00004.
A dry cough is the most common adverse effect of angiotensin converting enzyme (ACE) inhibitors, even if it is not particularly serious. Controlled studies have suggested that the incidence may eventually be as high as 20% and the problem seems to occur much more often in women.
The mechanism of the cough associated with ACE inhibitor treatment is unrelated to inhibition of the renin-angiotensin system because treatment with angiotensin receptor blockers and renin inhibitors has not caused similar problems. Other substrates of ACE have been implicated, and the side effect has been linked in particular to an accumulation of bradykinin or tachykinins in the airways with consequent stimulation of vagal afferents that subserve the cough reflex, particularly the non-myelinated or C fibres. Some of the effects of bradykinin in particular may be due to secondary activation of prostaglandins (PG), especially PGE2 and PGI2. Anecdotal evidence that cyclooxygenase inhibitors prevent the cough has not been sustained in well controlled clinical trials, but recent evidence suggests that inhaled cromoglycate may have a significant inhibitory effect. The mechanism of action of cromoglycate is not well understood but evidence of inhibition of local neural reflexes has been inferred, mostly from animal studies. The observation seems unlikely to have much practical benefit for it is difficult to envisage routine use of an inhaled agent to prevent a drug side effect. The question of whether ACE inhibitors are safe in patients with asthma is still open, and most rechallenge studies have shown little effect on lung function. Data from one large-scale surveillance study suggest that a few individuals may experience dyspnoea and wheezing but no causal relationship has been established.
Delineation of the mechanism of the ACE inhibitor cough may lead to a better understanding of the mechanism of cough in inflammatory airways disease.
干咳是血管紧张素转换酶(ACE)抑制剂最常见的不良反应,即便其并非特别严重。对照研究表明,其发生率最终可能高达20%,而且该问题在女性中似乎更为常见。
ACE抑制剂所致咳嗽的机制:与ACE抑制剂治疗相关的咳嗽机制与肾素 - 血管紧张素系统的抑制无关,因为使用血管紧张素受体阻滞剂和肾素抑制剂治疗并未引发类似问题。ACE的其他底物也受到牵连,这种副作用尤其与气道中缓激肽或速激肽的蓄积有关,进而刺激介导咳嗽反射的迷走传入神经,特别是无髓鞘或C纤维。缓激肽的某些作用可能尤其归因于前列腺素(PG)的继发性激活,特别是PGE2和PGI2。环氧合酶抑制剂可预防咳嗽这一传闻证据在严格控制的临床试验中并未得到证实,但最近的证据表明吸入色甘酸可能具有显著的抑制作用。色甘酸的作用机制尚不完全清楚,但已推断其具有抑制局部神经反射的作用,这主要基于动物研究。这一观察结果似乎不太可能有太大实际益处,因为很难设想常规使用吸入剂来预防药物副作用。ACE抑制剂在哮喘患者中是否安全这一问题仍未明确,大多数再次激发试验表明对肺功能影响不大。一项大规模监测研究的数据表明,少数个体可能会出现呼吸困难和喘息,但尚未确立因果关系。
对ACE抑制剂所致咳嗽机制的描述可能有助于更好地理解炎症性气道疾病中的咳嗽机制。